Sanctuary Wealth Management L.L.C. Decreases Position in Johnson & Johnson (NYSE:JNJ)

Sanctuary Wealth Management L.L.C. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 32.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 267 shares of the company’s stock after selling 126 shares during the quarter. Sanctuary Wealth Management L.L.C.’s holdings in Johnson & Johnson were worth $39,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Life Planning Partners Inc bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $21,441,000. RWA Wealth Partners LLC grew its position in Johnson & Johnson by 18.0% in the 4th quarter. RWA Wealth Partners LLC now owns 365,556 shares of the company’s stock valued at $52,867,000 after acquiring an additional 55,700 shares during the last quarter. Schroder Investment Management Group increased its stake in Johnson & Johnson by 18.1% in the fourth quarter. Schroder Investment Management Group now owns 1,847,350 shares of the company’s stock worth $267,164,000 after purchasing an additional 282,807 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of Johnson & Johnson by 105.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,366,660 shares of the company’s stock worth $342,266,000 after purchasing an additional 1,213,804 shares during the last quarter. Finally, American Money Management LLC boosted its stake in shares of Johnson & Johnson by 9.2% during the fourth quarter. American Money Management LLC now owns 37,404 shares of the company’s stock valued at $5,409,000 after purchasing an additional 3,148 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Up 0.3 %

Johnson & Johnson stock opened at $163.63 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market cap of $394.32 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The stock has a 50-day moving average of $158.68 and a two-hundred day moving average of $156.13. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.03%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on JNJ. Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Bank of America increased their price objective on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 5th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Finally, Citigroup dropped their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.